Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.
Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.
Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.
Abstract: Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity.
Abstract: The present invention features compositions that include one or more vitamin B12 compounds and one or more excipients that enhance solubility of the vitamin B12 compounds. In aspects of the invention, the excipients are alcohols, in particular ethanol, propylene glycol, a polyethylene glycol (PEG), glycerol, mannitol, sorbitol, Tween 20, or dimethylsulfoxide or a combination thereof, and/or a salt former. The compositions optionally comprise one or more therapeutic agents other than a vitamin B12 compound. The invention also contemplates processes by which the compositions can be made; kits containing them (or one or more of the components thereof); and methods of using them to treat patients who have a vitamin B12 deficiency, a proliferative disease, an inflammatory disease, or a viral disease.
Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.
Abstract: Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compound in combination with an interferon compound. Vitamin B12 compounds are administered separately, simultaneously or in combination with interferon compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
Abstract: The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. These tissue disorders are associated with a novel cellular phenotype designated as “transition cells” which are described herein. This cellular phenotype is characterized in having an activated erk kinase signaling activity, a stimulated AP-1 binding activity, and at least one characteristic selected from the group consisting of: (a) increased podosome formation, (b) increased flux of intracellular or extracellular hyaluronans or hyaladherins, (c) increased expression of a hyaladherin, (d) an inability to form focal adhesions, (e) increased metalloproteinase activity, and (f) increased expression of a hyaladherin. Example tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as occur in cancerous cells.
Type:
Grant
Filed:
October 15, 2001
Date of Patent:
June 28, 2005
Assignee:
Transition Therapeutics Inc.
Inventors:
Tony Cruz, Aleksandra Pastrak, Eva A. Turley
Abstract: Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compound in combination with an interferon compound. Vitamin B12 compounds are administered separately, simultaneously or in combination with interferon compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
Abstract: Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
Abstract: The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells. They are associated with a novel cellular phenotype (designated “transition cells”) which is characterized in having an activated erk kinase signaling activity; a stimulated AP-1 binding activity; and increased podosome formation, increased flux of intracellular or extracellular hyaluronans or hyaladherins, increased expression of a hyaladherin, an inability to form focal adhesions, and/or increased metalloproteinase activity. A novel cell culture comprising transition cells is provided, as well as compositions and methods using particular peptides, polypeptides, and antibodies that affect the transitional phenotype.
Type:
Application
Filed:
November 29, 2004
Publication date:
March 24, 2005
Applicant:
Transition Therapeutics Inc.
Inventors:
Tony Cruz, Aleksandra Pastrak, Eva Turley
Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.
Type:
Application
Filed:
April 27, 2004
Publication date:
October 7, 2004
Applicant:
Transition Therapeutics Inc., a Canada corporation
Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.
Abstract: Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
Abstract: Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compound in combination with an interferon compound. Vitamin B12 compounds are administered separately, simultaneously or in combination with interferon compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.